annual meeting 2015, abstract 3789; Cancer Research 2015, 75 (15 supplement) SHARE THIS POST Basilea Pharmaceutica NewsMORE your MARKET VIEW Related Stocks Find News …
Basilea plans progression of oncology candidate lisavanbulin to targeted, biomarker-driven phase 2 study
Basilea plans progression of oncology candidate lisavanbulin to targeted, biomarker-driven phase 2 study
Leave a reply